SB Drug Discovery is excited to announce a significant advancement in its screening capabilities with the integration of the state-of-the-art SURFE2R 96SE. Enabling high throughput solid supported membrane-based electrophysiology and supporting critical lead optimization, the SURFE2R 96SE automated platform will revolutionize transporter research, opening new avenues for electrogenic transporter drug discovery.
With its capacity for parallel recordings from 96 wells and the ability to collect up to 10,000 data points daily, this platform allows for in-depth analysis of transporter function in real-time. This breakthrough technology also eliminated the need for labels, radioactivity, or fluorescence, providing a safe, efficient, and highly accurate method for transporter research.
Hear from our experts
Ian McPhee, Scientific Director, SB Drug Discovery
“With the introduction of the SURFE2R 96SE, SB Drug Discovery’s capacity for conducting transporter research has been elevated to a new level. This cutting-edge platform facilitates high-throughput data collection, expediting transporter drug discovery research and enriching the quality and depth of our analyses. Additionally, our scientists have designed and optimized a range of transporter-expressing cell lines and functional cell-based assays, providing invaluable tools to identify modulators of these promising therapeutic targets.”
Interested in learning more?
For more information about SB Drug Discovery and our advancements in transporter drug discovery research, get in touch today.
